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Abstract
Background:  Schizophrenia is often a persistent and costly illness that requires continued
treatment with antipsychotics. Differences among antipsychotics on efficacy, safety, tolerability,
adherence, and cost have cost-effectiveness implications for treating schizophrenia. This study
compares the cost-effectiveness of oral olanzapine, oral risperidone (at generic cost, primary
comparator), quetiapine, ziprasidone, and aripiprazole in the treatment of patients with
schizophrenia from the perspective of third-party payers in the U.S. health care system.
Methods:  A 1-year microsimulation economic decision model, with quarterly cycles, was
developed to simulate the dynamic nature of usual care of schizophrenia patients who switch,
continue, discontinue, and restart their medications. The model captures clinical and cost
parameters including adherence levels, relapse with and without hospitalization, quality-adjusted
life years (QALYs), treatment discontinuation by reason, treatment-emergent adverse events,
suicide, health care resource utilization, and direct medical care costs. Published medical literature
and a clinical expert panel were used to develop baseline model assumptions. Key model outcomes
included mean annual total direct cost per treatment, cost per stable patient, and incremental cost-
effectiveness values per QALY gained.
Results: The results of the microsimulation model indicated that olanzapine had the lowest mean
annual direct health care cost ($8,544) followed by generic risperidone ($9,080). In addition,
olanzapine resulted in more QALYs than risperidone (0.733 vs. 0.719). The base case and multiple
sensitivity analyses found olanzapine to be the dominant choice in terms of incremental cost-
effectiveness per QALY gained.
Conclusion: The utilization of olanzapine is predicted in this model to result in better clinical
outcomes and lower total direct health care costs compared to generic risperidone, quetiapine,
ziprasidone, and aripiprazole. Olanzapine may, therefore, be a cost-effective therapeutic option for
patients with schizophrenia.
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Background
Schizophrenia is often a debilitating, persistent, and
costly disorder. Although it afflicts only about 1% of the
U.S. population [1], it imposes a disproportionately large
economic burden relative to other mental illnesses and
nonpsychiatric medical disorders [2]. The most recent
cost-of-illness study in the United States [3] estimated
schizophrenia to cost $62.7 billion in the year 2002, with
total direct medical costs being driven primarily by the
utilization of health care resources in treating symptom
relapses.
Antipsychotics are considered the core treatment regimen
for schizophrenia, aimed at reducing the risk of relapse
and enhancing long-term functional outcomes [4].
Although patients are expected to be on their medications
for a prolonged time – often a lifetime [4], a majority
(58%) of patients are nonadherent to antipsychotic ther-
apy [5]. Studies have shown that nonadherence to antip-
sychotic therapy is associated with an increased risk of
relapse and inpatient psychiatric hospitalization [6-14],
the costliest components in treating schizophrenia [15-
19].
Studies examining adherence among patients with schiz-
ophrenia have demonstrated that adherence is not an "all
or none" phenomenon because many patients appear to
be partially adherent [7,20,21], not taking their medica-
tions as prescribed, and/or having gaps in medication
intake [16,18,20,22]. Prior research [23-25] has docu-
mented the dynamic nature of treatment with antipsy-
chotics where patients start, switch, continue, and
discontinue their antipsychotics for various reasons,
including patient decision, lack of medication efficacy,
and medication intolerability.
A large number of studies have found different adherences
[26-32] and persistence [23-25,33-51] among antipsy-
chotic medications. Although it was long believed that
patients with schizophrenia discontinue their medica-
tions primarily due to treatment-emergent adverse events,
more recent studies have reported that lack of medication
efficacy is a more prevalent driver of treatment discontin-
uation compared to medication intolerability [23-25,52].
Furthermore, patients who experience better treatment
outcomes tend to perceive their medication as more ben-
eficial and are more likely to persist taking them [53-55].
As a result, the differential clinical benefits among antip-
sychotic medications have a variety of cost-effectiveness
implications for patients, third-party payers, and society.
Most prior research on the cost-effectiveness of antipsy-
chotics in the treatment of schizophrenia has compared
first-generation antipsychotics (FGAs) and second-genera-
tion antipsychotics (SGAs) [17,49,56,57]. Although stud-
ies have reached different conclusions regarding the cost-
effectiveness of 1 or more SGAs versus FGAs [17,49,57],
the debate about the relative benefits of FGAs versus SGAs
has become less relevant for U.S. payers, who may have
little incentive to use FGAs following patent expiry of ris-
peridone and its availability in generic form and lower
cost. The economic environment appears to be changing
after oral risperidone, the most frequently used SGA for
the treatment of schizophrenia in the United States, has
become available in generic form in July 2008. We antici-
pate increased interest in cost-effectiveness models that
compare generic oral risperidone with other frequently
used oral SGAs to address payers' questions concerning
the relative cost-effectiveness of the various SGAs given
the growing economic constraints in the U.S. health care
system.
The broad objective of this study is to create an economic
decision model to compare the relative clinical benefits,
associated direct medical costs, and cost-effectiveness of
oral olanzapine, oral generic risperidone (primary compa-
rator), quetiapine, ziprasidone, and aripiprazole in the
usual treatment of schizophrenia from the perspective of
third-party payers in the U.S. health care system.
In this paper, we first present a conceptual structure of the
model and identify sensitivity analysis conducted. We
then review baseline assumptions for key clinical and eco-
nomic inputs. Next, we report results for the baseline
assumptions and the results of 1-way sensitivity analyses
where discrete changes in the input values for key varia-
bles are evaluated for their impact on results. We also
include results of probabilistic sensitivity analyses (PSA)
where inputs for multiple variables are sampled from dis-
tributions for multiple cohorts. The paper concludes with
a discussion, limitation of the model, and summary.
Methods
Model Structure and Study Design
A Monte Carlo Microsimulation (MCM) model was devel-
oped to compare the cost-effectiveness of 5 frequently
used oral atypical antipsychotics in the usual care of schiz-
ophrenia in the United States. Results are based upon a
simulation of 1,000,000 patients. The target patient pop-
ulation was community-dwelling adult patients with
schizophrenia who had a history of schizophrenia. The
model compares oral olanzapine with generic oral risperi-
done (primary comparator), quetiapine, ziprasidone, and
aripiprazole in the treatment of patients with schizophre-
nia for a 1-year study period. Health care costs are evalu-
ated from the perspective of a public or private third party
health care payer in the United States. The model simu-
lates the dynamic nature of usual care where patients
switch, continue, discontinue, and restart their antipsy-
chotics in quarterly cycles. The choice of quarterly cycles isCost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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based on previous cost-effectiveness research [58] and
expert consensus that the duration of an "adequate antip-
sychotic treatment trial" [25,58,59] is 3–8 weeks if there is
no response and 5–12 weeks if there is a partial response
before switching to another pharmacologic strategy. The
MCM model captures clinical outcomes and estimates
third-party payers' costs. The MCM model allows for a
number of input parameters including: adherence levels,
relapse with and without hospitalization, health state util-
ities, treatment discontinuation by reason, treatment-
emergent adverse events, health care resource utilization,
and health care costs, including medication costs. Key
clinical outcomes predicted include psychiatric inpatient
hospitalization rates and quality-adjusted life years
(QALYs). Costs are expressed in U.S. dollars based on
2007 values. The MCM model assumes an intent-to-treat
approach that attributes all estimated direct medical costs
to the initial therapy.
Although schizophrenia is a chronic illness that requires
long-term treatment, we chose a 1-year timeframe for the
MCM model because 1 year is the time period the typical
third-party payer is responsible for covering medical costs
of a covered life. In addition, the dynamic nature of the
treatment for schizophrenia with its high rate of medica-
tion switching and discontinuation makes it difficult to
directly relate the initial treatment selection to the final
cost-effectiveness outcomes in a multiyear study period.
Furthermore, projections of total medical costs from a
third-party payer perspective may not be very useful
beyond a 1-year time horizon due to shifts in drug pricing,
reimbursement rates, turnover of plan membership, and
changes in benefit design.
Figure 1 presents a conceptual overview of the usual treat-
ment for patients living in the community where patients
are initiated on specific antipsychotic medications and
manifest various adherence levels (fully adherent, par-
tially adherent, or nonadherent). Depending on their
adherence level, the patients may (a) remain stable, (b)
suffer relapse(s) requiring hospitalization, or (c)
relapse(s) not severe enough to warrant psychiatric hospi-
talization. The patients could potentially experience treat-
ment-emergent adverse events: extrapyramidal symptoms
(EPS), clinically significant weight gain (≥ 7%), diabetes,
or hyperlipidemia. Depending on benefits and/or adverse
Conceptual View of MCM Model Figure 1
Conceptual View of MCM Model.Cost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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events on the initiated medication, the patients and/or
their treating physicians decide whether to continue or
discontinue the medication. Medication discontinuations
involve either a switch to another antipsychotic or discon-
tinuing antipsychotic treatment for awhile. The model
takes into account switching patterns, incorporating the
primary reason for medication discontinuation (poor effi-
cacy, intolerability, patient decision, or other reasons). As
patients with schizophrenia are at a high risk of suicide,
the model also incorporates the risk of attempted and
completed suicide [60]. The patient's health state at the
end of the first quarter constitutes the base for the
patient's health state in the next quarter until the end of
the fourth quarter (1 year). In addition, certain adverse
events (i.e., diabetes and hyperlipidemia) were assumed
to remain "with" the patient for the remaining periods,
since these adverse events may not disappear within the 1-
year timeframe and, therefore, contribute to treatment
costs for the remainder of the study period.
Sequential Bifurcation Test
The MCM model is designed to capture clinically relevant
variables for patients with schizophrenia in the usual care
setting. However, important clinical variables do not
always impact total treatment costs or cost-effectiveness
results due to low incidence, low cost, or both. As a result,
we used sequential bifurcation [61] to screen all model
inputs to determine those variables impacting total treat-
ment costs that warrant focus in sensitivity analyses.
Sequential bifurcation is a process that iteratively samples
inputs within relevant input ranges and assesses the
impact of each input against a predetermined threshold
value. For each of the iterations, factors that impact results
at or above the threshold value are used in the next itera-
tion. This process continues until there remains no new
factor that impacts model outputs by the specified thresh-
old value. Overall, the analyses tested 16 groups with 11
distinct variables examining the impact of variation in
over 120 different input assumptions.
The results of the sequential bifurcation tests demon-
strated that not all variables that are clinically relevant
impact economic outcomes. The suicide rate for patients
with schizophrenia is an example of a clinically relevant
input, but the sequential bifurcation confirms that it does
not impact economic outcomes because of its relatively
low incidence rate. In addition, the sequential bifurcation
test found that the majority of the costs associated with
failed suicide attempts are captured in the treatment cost
of an inpatient relapse. Further, cost incurred after a com-
pleted suicide are mainly societal and as such, generate no
additional costs in our model, and the simulation ends for
that patient. Therefore, input assumptions for the suicide
rate are modifiable in the MCM model, but this variable is
not included in the sensitivity analyses.
One-Way Sensitivity Analyses
The sequential bifurcation tests indicate that the key eco-
nomic outcomes of the MCM model include the number/
cost of unit health care resources, relapse rates, initial
adherence rates, and conditional probabilities of relapse
given a history of relapse. As a result, we conducted single
variable sensitivity analyses to examine the impact of dis-
crete changes in the value of these variables on the
model's results. Specifically, we performed the following
5 analyses:
1. Sensitivity on adherence rates;
2. Sensitivity on adverse event rates;
3. Sensitivity on relapse rates expressed as inpatient
hospitalization risk ratios;
4. Sensitivity for olanzapine versus risperidone, chang-
ing CATIE relapse risk ratio to achieve desired ICER
result.
5. Variation in the cost per day of therapy for generic
risperidone.
It should be noted that 1-way sensitivity analysis was not
conducted on key input variables that did not vary
between the 5 antipsychotic medications, such as the cost
of most health care resources.
Probabilistic Sensitivity Analyses
We conducted 2 multivariable PSAs to examine the uncer-
tainty in the model and the stability of the results. The first
PSA allowed the input values for adherence rates, relapse
rates, treatment discontinuation rates, and the generic cost
of risperidone to be randomly drawn from independent
distributions of possible input values. With the exception
of the generic cost of risperidone, the range of possible
input values was created by setting the minima and
maxima of the range to be 50% and +50% of the base case
value. The second PSA extended the first analysis by add-
ing distributions around the number and cost of resources
consumed for stable patients (no relapse), patients expe-
riencing inpatient relapse, and patients experiencing out-
patient relapses. In both PSAs, the results were based on
1,000 cohorts of 1,000 patients each.
Key Clinical and Economic Input Values
The sequential bifurcation analysis identified a number of
key clinical and economic inputs. The remainder of this
section reviews the development of the baseline assump-
tion for these key inputs, which were based, when possible,
on evidence reported in peer-reviewed articles. Information
reported in these articles is used to derive baseline assump-
tions for each of the 5 antipsychotic medications.Cost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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Adherence Levels
Adherence to antipsychotic therapy in the MCM model is
based on the annual medication possession ratio (MPR),
the number of days with the medication prescribed by the
total number of days in a given period [16,28,30-32]. The
MCM model allowed for patients to be categorized into 1
of 3 adherence levels: fully adherent (MPR >/= 80%), par-
tially adherent (60% </= MPR < 80%), or nonadherent
(MPR < 60%) [22]. The baseline assumptions of the pro-
portion of patients who fall into the full, partial, or non-
adherent categories are based on the information
contained in the only published latent class analysis
reporting adherence rates of an antipsychotic medication
for patients in the United States [62]. In order to derive
differential adherence distributions (for fully, partially, or
nonadherent patients) for the 5 antipsychotic medica-
tions, we made the following assumptions: 1) the results
for haloperidol, a typical antipsychotic reported in Ahn
[62], represent the lower bound of adherences for the
MCM model because the findings are based on Medicaid
patients; 2) we then used the annual MPR ratios reported
in Ascher-Svanum [31] by medication (olanzapine = 75%;
risperidone = 69%; quetiapine = 61%, and haloperidol =
49%) to produce an adjustment factor for each adherence
level for these medications; 3) proportion of patients at
each adherence level for ziprasidone and aripiprazole
were assumed to be equal to quetiapine as in a previous
cost-effectiveness study [18]. Table 1, Part A, reports the
MCM model's baseline adherence rates by adherence cat-
egory for each study medication.
The MCM model also requires a set of assumptions con-
cerning expected level of adherence in subsequent cycles
following a relapse in the previous quarterly cycle.
Because of the lack of published data by reporting this
information for the study medications, all patients in the
MCM model were assumed to change their level of adher-
ence primarily through relapse. Table 1, Part B, reports
these baseline assumptions concerning adherence rates in
the cycle following a relapse. The variation in baseline
assumptions based on the adherence category in previous
quarterly cycles were based on a new analysis of the U.S.
Schizophrenia Care and Assessment Program (US-SCAP)
data conducted to examine how adherence levels change
from pre- to post-relapse [22]. US-SCAP is a large, 3-year,
prospective, naturalistic, observational, noninterven-
tional, multisite study of persons treated for schizophre-
nia across the United States [12,63,64].
Relapse Rates
The MCM model requires a series of assumptions con-
cerning patients' adherence levels and relapse rate for each
of the study medications. One study – sponsored by the
National Institute of Mental Health (NIMH) – the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE)
[23] provided the data on relapse rates. This large, rand-
omized, double-blind study provides relapse rates for 4 of
the 5 antipsychotics included in our model for an 18-
month study period. This independent study is the only
one to provide relapse data for each of the studied 4 atyp-
ical antipsychotics in the treatment of chronically ill schiz-
Table 1: Adherence Input Values
Part A: Adherence Rates by Medication
Medications Full Partial Non
Olanzapine 23% 43% 34%
Risperidone 21% 39% 40% Ahn et al., 2007 [62];
Ascher-Svanum et al., 2009 
[22]
Quetiapine 19% 35% 46%
Ziprasidone 19% 35% 46% Assumed equal to 
quetiapine
Aripiprazole 19% 35% 46% Assumed equal to 
quetiapine
Part B: Adherence Rate by Level in Cycle Following Relapse
Adherence Level Prior 
to Relapse






Full adherence 92.03% 1.45% 6.52%
Partial adherence 75.00% 12.50% 12.50% Ascher-Svanum et al., 2009 
[22]
Nonadherence 38.70% 9.70% 51.60%Cost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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ophrenia patients in the United States. Results from the
primary phase of CATIE, phase 1 [23], found significant
differences among the antipsychotics for relapses requir-
ing hospitalization, with olanzapine therapy having the
lowest risk of relapse (number of hospitalizations/total
person-year of exposure). The reported hospitalization
risk ratios for the 4 medications of interest were 0.29× for
olanzapine, 0.45× for risperidone, 0.66× for quetiapine,
and 0.57× for ziprasidone. Table 2, Part A, presents the
MCM model's baseline assumptions for the risk of an ini-
tial relapse resulting in an inpatient hospitalization by
adherence category for each medication. We used the fol-
lowing 3-step process to estimate these relapse rates. First,
a baseline relapse rate by adherence level was adopted
from a study by Gilmer and colleagues [16] among Med-
icaid patients. Second, the relapse rates for olanzapine,
quetiapine, risperidone, and ziprasidone were derived
using the hospitalization risk ratios reported from CATIE
phase 1 [23]. Consistent with a prior model comparing
the cost-effectiveness of antipsychotics in the treatment of
schizophrenia [18], we also assumed that the rates of
relapse for aripiprazole are equivalent to ziprasidone. This
was done because no comparative data are available for
aripiprazole versus the other 4 studied atypicals on relapse
rates as the CATIE study did not include aripiprazole.
Finally, we assumed a constant proportion of inpatient-
to-outpatient rates of relapse by adherence level; 1.0 for
fully adherent; 1.13 for partially adherent; and 1.11 for
nonadherent for all antipsychotic medications studied
[18].
In addition, the MCM model requires a set of conditional
probabilities to allow for: 1) multiple outpatient relapses
within a single quarter, 2) multiple inpatient relapses
within a single quarter, and 3) higher rates of inpatient
relapse given a history of inpatient relapse. First, we
Table 2: Relapse Input Values
Parameter Value Data Source
Part A:
Relapse Rates Requiring Hospitalization – 
For Initial Relapse
Full Adherence Partial Adherence Non-Adherence
Olanzapine 2.0% 3.6% 5.2%
Risperidone 3.2% 5.8% 8.8% Lieberman et al, 2005 [23];
Quetiapine 4.9% 8.8% 14.0% Gilmer et al, 2004 [16]
Ziprasidone 4.2% 7.4% 11.6%
Aripiprazole 4.2% 7.4% 11.6% Assumed equal to ziprasidone
Relapse Rates Not Requiring 
Hospitalization
Full Adherence Partial Adherence Non-Adherence
Olanzapine 2.0% 3.2% 4.8% Lieberman et al, 2005 [23];
Risperidone 3.2% 5.1% 7.9% Gilmer et al, 2004 [16];
Quetiapine 4.9% 7.8% 12.6% Edwards et al, 2005 [18]
Ziprasidone 4.2% 6.6% 10.5%
Aripiprazole 4.2% 6.6% 10.5% Assumed equal to ziprasidone
Part B:
Adjusted Relapse Rates Given a History of 
Relapse
Full Adherence Partial Adherence Non-Adherence
Probability given history of 1 relapse 19% 40% 58%
Probability given history of 2 relapses 36% 75% 100% Olfson et al., 2000 [65];
Tiihonen et al., 2006 [66]
Probability given history of 3 relapses 42% 88% 100%
Part C:
Probability of Suicide Event Given 
Adherence Level
Fully Adherent Partially Adherent Non-Adherent
Probability of suicide attempt 0.25% 0.76% 1.00% Ahn et al., 2007 [62]
Probability suicide attempt is fatal 10.00% Siris 2001 [60]
Cost of non-fatal suicide attempt $140 (in addition to relapse costs) Assumption
Cost of fatal suicide attempt $0 AssumptionCost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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assumed if a patient had an inpatient relapse, there was a
20% probability of the occurrence of another inpatient
relapse during the same quarter [18]. If the first event was
an outpatient relapse, then there was a 75% chance of
another outpatient relapse during that quarter [18]. Sec-
ond, the probabilities of having an inpatient relapse given
1 inpatient relapse in a previous quarter across adherence
categories was adjusted to reflect the impact of adherence
on relapse found in prior research [65,66] which reported
that in the 3 months following a relapse, 19% of fully
adherent (> 80% MPR) and 43% of nonadherent patients
(< 80% MPR) experienced relapses. We set the probability
of a second relapse at 19% for patients fully adherent and
distributed the probability of a second relapse (43%)
between the partially adherent and nonadherent groups
weighted by the mean baseline proportion of individuals
in each group. These steps result in the baseline assump-
tions reported in Table 2, Part B. It should be noted that
using these baseline rates in the MCM model results in a
weighted average number of relapses that is nearly identi-
cal to the crude rate of relapse for individuals with a his-
tory of 1 relapse reported in the literature (0.47 vs. 0.46)
[36].
Treatment-emergent Adverse Events
The MCM model requires assumptions about the likeli-
hood of patients experiencing 4 types of potential treat-
ment-emergent adverse events: EPS, clinically significant
weight gain (≥ 7% weight gain from baseline weight), dia-
betes, and hyperlipidemia for each medication. Table 3
reports all baseline assumptions concerning adverse
events by medication. EPS rates for olanzapine and risp-
eridone are based on results from an integrated analysis of
23 clinical trials that compared incidences of EPS, dys-
tonic, parkinsonian, and akathisia events [67]. EPS rates
for quetiapine and ziprasidone are based on package
insert information, while the rate for aripiprazole is based
on a 1-year randomized, double-blind study comparing
olanzapine and aripiprazole in the treatment of patients
with schizophrenia [68]. Baseline assumptions concern-
ing potentially clinically significant weight gain for all
treatments except aripiprazole are based on the CATIE
phase 1 results [23]. Baseline assumptions for event rates
for emergent diabetes for olanzapine, risperidone, and
quetiapine are based on Lambert et al. [69]. Due to the
lack of data for treatment-emergent diabetes for ziprasi-
done and aripiprazole, we make the assumption that their
Table 3: Adverse Event Values
Parameter Value Data Source
Adverse Event Rates for EPS
Olanzapine 15.5% Carlson et al., 2003 [67]
Risperidone 24.7%
Quetiapine 8.0% Package insert, revised 10/2007
Ziprasidone 14.0% Package insert, revised 07/2007
Aripiprazole 21.0% Fleischhacker et al., 2008 [68]
Adverse Event Rates for Clinically Significant Weight Gain (≥ 7%)
Olanzapine 30.0%
Risperidone 14.0% Lieberman et al., 2005 [23]
Quetiapine 16.0%
Ziprasidone 7.0%
Aripiprazole 7.3% Fleischhacker et al., 2008 [68]
Adverse Event Rates for Diabetes
Olanzapine 3.3%
Risperidone 3.2% Lambert et al., 2006 [69]
Quetiapine 3.6%
Ziprasidone 2.0% Assumed equal to Lambert et al., 2006 [69] lowest reported rate, that for typicals
Aripiprazole 2.0%
Adverse Event Rates for Hyperlipidemia
Olanzapine 16.8%
Risperidone 14.0% Lieberman et al., 2005 [23]
Quetiapine 14.1% Lambert et al., 2005 [70]
Ziprasidone 8.1% Olfson et al., 2006 [71]
Aripiprazole 3.6%Cost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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rates are the lowest rates reported in the Lambert et al.
study [69] (equal to typical antipsychotics). The rates for
treatment-emergent hyperlipidemia were based on base-
line rates reported for all CATIE participants [23] adjusted
to rates reported in 2 California Medicaid studies [70,71].
The differential in baseline rates for EPS and potentially
clinically significant weight gain for aripiprazole were
based upon results of a double-blind, randomized com-
parative study of aripiprazole versus olanzapine [68].
Finally, the MCM model requires a baseline assumption
concerning the proportion of patients developing coro-
nary heart disease (CHD) overall and conditional on hav-
ing diabetes or metabolic syndrome. The MCM model
used a quarterly baseline rate of 0.25% for the probability
of developing CHD, calculated to be consistent with the
model's 1-year timeframe using the Framingham risk
equation [23,72,73] and assumed a relative risk of 2.67 of
CHD given diabetes [74] and 4.47 relative risk of CHD
given metabolic syndrome [74].
Medication Discontinuation Rates
The MCM model allows patients to discontinue therapy
for various reasons and from any health state, including
stable patients without a treatment-emergent adverse
event. The model allows for 4 major reasons for discontin-
uation: 1) Lack of efficacy, 2) Medication intolerability, 3)
Patient decision, and 4) Other reason. Baseline assump-
tions concerning discontinuation rates from all health
states in the model were calculated to yield the annual dis-
continuation rates based on the survival curves from the
18-month long CATIE phase 1 [23]. The integration of the
CATIE phase 1 results and the model states was accom-
plished by repeated calibration of a multivariable system
of equations. The final effect was that the sum of model-
specific estimates of discontinuation from all states in the
model, including each type of adverse event, matches the
annual CATIE phase 1 discontinuation rates for any cause.
These annual rates for each study medication are reported
in Table 4. The annual discontinuation rate for aripipra-
zole is based upon a head-to-head trial with olanzapine
[68] and the distribution by reason for discontinuation
for aripiprazole was created using the same proportions as
ziprasidone in CATIE, assuming that ziprasidone and
aripiprazole possess similar efficacy and tolerability pro-
files [18]. Table 4 also reports how the baseline discontin-
uation rates for each medication are distributed across the
4 reasons for discontinuation [23]. For each medication,
the sum of the discontinuation rates across the 4 reasons
equals the annual all-cause discontinuation rate.
Medication Switching Patterns
The MCM model requires a set of assumptions regarding
the switching patterns that takes into account the reason
for the switch and attempts to choose subsequent treat-
ments that relate to that reason. For example, discontinu-
ation due to EPS would result in a switch to treatments
with a more favorable EPS profile. The same approach was
used to estimate switching patterns for clinically signifi-
cant weight gain, diabetes, hyperlipidemia, lack of medi-
cation efficacy (a relapse), or patient decision. As such, the
options for treatments to "switch to" are dependent on
the treatment a patient is "switched from" and are consist-
ent with the comparative efficacy and tolerability of the
antipsychotics studied and reported for the CATIE [23-25]
and other research [19,75]. Table 5 presents the medica-
tion-switch patterns (the medication one is switched from
and the medication one is switched to) for each of the 5
reasons for the switching.
Utility and quality-adjusted life year
Disease-specific utility values for 8 schizophrenia disease
states have been reported by Lenert and colleagues [76]
Table 4: Treatment Discontinuation Rates
Parameter Value Data Source
Annual All-Cause Discontinuation Rates
Olanzapine 54.0%
Risperidone 63.0% Lieberman et al., 2005 [23]
Quetiapine 76.0%
Ziprasidone 74.0%
Aripiprazole 61.0% Fleischhacker et al., 2008 [68]
Annual Discontinuation Rates by Reason
Lack of Efficacy Intolerability Patient Decision Other
Olanzapine 13% 16% 20% 5%
Risperidone 22% 10% 22% 9% Lieberman et al., 2005 [23]
Quetiapine 27% 14% 29% 6%
Ziprasidone 25% 13% 30% 6%
Aripiprazole 15% 18% 23% 5% Fleischhacker et al., 2008 [68]Cost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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using the Positive and Negative Syndrome Scale. Table 6
reports the baseline utility values assigned to each of the 9
possible combinations of adherence levels (full, partial, or
nonadherence) and the relapse results (stable, outpatient
relapse, or inpatient relapse) required by the MCM model.
A panel of 12 independent schizophrenia experts was
used to develop these values as follows. First, we surveyed
(via email) the panel of experts to determine which of
Lenert and colleagues' 8 possible health states best
matched the utility of a schizophrenia patient in each of
the MCM model's 9 possible adherence/relapse out-
comes. Next, we rounded the averaged survey response to
the nearest whole number and assigned this number the
appropriate utility value reported by Lenert and col-
leagues [76]. Table 6 also reports baseline assumptions
concerning disutility among patients experiencing 1 of the
model's 4 treatment-emergent adverse events: EPS, clini-
cally significant weight gain, diabetes, and hyperlipi-
demia. The disutility multipliers reported for EPS and
clinically significant weight gain were derived from those
reported by Lenert and colleagues [76]. We assumed that
utilities among patients experiencing diabetes or hyperli-
pidemia were equal to that of patients experiencing EPS,
as we are unaware of any peer-reviewed utility informa-
tion for patients with schizophrenia experiencing diabetes
or hyperlipidemia.
Table 5: Treatment Switch Patterns by Reason for Switching and by Antipsychotic:
Medication Switch To → Olanzapine Risperidone Quetiapine Ziprasidone Aripiprazole Clozapine
Medication Switched From ↓ by Reason
Lack of Efficacy
Olanzapine 0% 20% 10% 20% 20% 30%
Risperidone 30% 0% 20% 20% 20% 10%
Quetiapine 20% 20% 0% 20% 20% 20%
Ziprasidone 30% 20% 20% 0% 30% 0%
Aripiprazole 20% 20% 20% 30% 0% 0%
Clozapine 0% 0% 0% 0% 0% 0%
Weight Gain
Olanzapine 0% 10% 10% 35% 45% 0%
Risperidone 0% 0% 10% 45% 45% 0%
Quetiapine 0% 30% 0% 35% 35% 0%
Ziprasidone 0% 0% 100% 0% 0% 0%
Aripiprazole 0% 0% 0% 5% 95% 0%
Clozapine 0% 20% 0% 40% 40% 0%
Diabetes
Olanzapine 0% 10% 10% 35% 45% 0%
Risperidone 0% 0% 10% 45% 45% 0%
Quetiapine 0% 30% 0% 35% 35% 0%
Ziprasidone 0% 0% 100% 0% 0% 0%
Aripiprazole 0% 0% 0% 5% 95% 0%
Clozapine 0% 20% 0% 40% 40% 0%
EPS
Olanzapine 0% 0% 30% 0% 30% 40%
Risperidone 40% 0% 30% 0% 30% 0%
Quetiapine 50% 0% 0% 0% 40% 10%
Ziprasidone 50% 0% 30% 0% 20% 0%
Aripiprazole 50% 0% 40% 0% 0% 10%
Clozapine 0% 0% 0% 0% 0% 100%
Hyperlipidemia
Olanzapine 0% 10% 10% 35% 45% 0%
Risperidone 0% 0% 10% 45% 45% 0%
Quetiapine 0% 30% 0% 35% 35% 0%
Ziprasidone 0% 0% 100% 0% 0% 0%
Aripiprazole 0% 0% 0% 5% 95% 0%
Clozapine 0% 20% 0% 40% 40% 0%
Patient Preference
Olanzapine 0% 50% 10% 20% 20% 0%
Risperidone 30% 0% 20% 20% 20% 0%
Quetiapine 20% 50% 0% 10% 10% 0%
Ziprasidone 20% 50% 10% 0% 10% 0%
Aripiprazole 20% 50% 10% 10% 0% 0%
Clozapine 0% 0% 0% 0% 0% 100%Cost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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Medication Costs
The cost of atypical antipsychotic medication is related to
daily dose levels, which in turn are linked to patients' ill-
ness severity. In order to use comparable medication doses
for the treatment of patients with schizophrenia who man-
ifest similar illness severity profiles, we used daily dose lev-
els reported in published, randomized, controlled,
schizophrenia studies [23,77,78]. Table 7, Part A, reports
baseline model assumptions concerning dosing and cost
for each medication. With the exception of generic risperi-
done, medication costs reflect 2007 net wholesale price
(NWP) [79]. We used NWP instead of average wholesale
price (AWP) because most third-party payers negotiate
price discounts. In addition, we conducted a separate PSA
that allowed medication costs to range from 20% above
AWP to 50% below AWP for each study medication. These
results are not reported because they did not materially
change key cost-effectiveness results. Since the cost of
generic risperidone is fluctuating at present, we estimated
its average cost during the first year post-patent expiry to be
at a 58% discount from its 2007 NWP [19].
Resource Utilization
The model requires resource utilization assumptions for 8
different types of health care services (hospitalization
days, day hospital treatment days, emergency room visits,
physician visits, mental health clinic visits, home care
hours, group intervention hours, and nutritionist visits)
across 5 patient outcomes (units per stable quarter, inpa-
tient relapse event, outpatient relapse event, EPS, and
potentially clinically significant weight gain). It is
assumed that treatment-emergent diabetes and hyperlipi-
demia would be treated in the normal course of quarterly
medical care. As such, there are no discrete units of utili-
zation assigned to these events, but they are represented
by aggregated quarterly costs for routine care and addi-
tional pharmacy costs [80,81]. Table 7, Part B, reports
baseline assumptions for health care utilization in treat-
ing 5 patient outcomes: stable quarters (no relapse), per
outpatient relapse, per inpatient relapse, EPS, and clini-
cally significant weight gain. The MCM model set baseline
length of stay for psychiatric inpatient hospitalization on
values reported by the Healthcare Cost and Utilization
Project (HCUP) Nationwide Inpatient Sample [82]. All
other baseline utilization assumptions are consistent lev-
els reported in prior U.S. cost-effectiveness research [18].
Health Service Resource Costs
The model requires resource cost assumptions for 3 types
of acute health care services (inpatient hospitalization per
day, day hospital treatment per day, and emergency room
visit) and 5 outpatient health care services (physician vis-
its, mental health clinic visits, home care hours, group
intervention hours, and nutritionist visits). These baseline
cost assumptions are reported in Table 7, Part C. All unit
costs assumptions are inflated to reflect the value of 2007
U.S. dollars using the medical services component of the
consumer price index [83].
Cost of Adverse Events
The MCM model also captures the direct health care cost
associated with treating 3 types of treatment-emergent
adverse events: diabetes, hyperlipidemia, and EPS. The
MCM model assumes that the quarterly cost of all health
care utilization associated with the treatment of emergent
diabetes is $600 per quarter based on the findings of Les-
lie and Rosenheck [84]. The baseline assumption for the
quarterly costs of statins for hyperlipidemia therapy is
$225 and is based on a 50% market share of 40 mg
generic statins and a 50% market share of branded statins
[80]. The baseline cost of treating EPS with anticholiner-
gics is assumed to be $12 per quarter based on the cost of
benztropine (2 mg/day) [18]. Finally, the MCM model
assumes all patients, regardless of initiated antipsychotic,
undergo metabolic monitoring per published expert con-
sensus guidelines [81] and include lab costs for fasting
Table 6: Utility Values for Health States and Disutility Multipliers for Treatment-emergent Adverse Events
Parameter Value Data Source
Health States Full Adherence Partial Adherence Non-Adherence
While Stable 0.88 0.75 0.75 Lenert et al., 2004 [76];
Outpatient Relapse 0.74 0.65 0.65 Expert opinion
Inpatient Psychiatric Relapse 0.53 0.53 0.42
Treatment-Emergent Adverse 
Events
EPS 0.888 Lenert et al., 2004 [76]
Clinically Significant Weight Gain 0.959
Diabetes 0.888 Assumption: diabetes, hyperlipidemia, and 
Metabolic syndrome;
Hyperlipidemia 0.888 utilities equal EPS utility in Lenert et al., 
2004 [76]
EPS = extra-pyramidal symptomsCost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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Table 7: Economic Input Parameters
A: Medication Costs
Cost Mean Modal Daily Dose (mg)
Olanzapine $15.44 15 NWP Prices, 
Analysource Data, 




$5.00 4 Doses: Conley and 
Mahmoud, 2001 
[77];
Quetiapine $14.79 500 Tunis et al., 2006 
[49];
Ziprasidone $9.81 100 Lieberman et al., 
2005 [23]; Kern et 
al., 2006 [78];
Aripiprazole $10.92 15 Generic 
risperidone NWP 
price = $5.00 per 
4 mg/day
B: Health Service Resource Utilization














0.0 0.0 11.7** 0.0 0.0
Day hospital 
treatment, day
0.0 1.25 1.25 0.0 0.0
Emergency room 
visits
0.0 1.0 1.0 0.0 0.0




4.5 2.0 2.0 1.0 2.5 **AHRQ HCUP 
[82]
Home care hour 0.0 2.75 2.75 0.0 0.0
Group 
intervention hour
1.5 1.5 1.5 0.0 5.0
Nutritionist visits 0.0 0.0 0.0 0.0 2.5
C: Unit Costs of Health Service Resources
Inpatient hospital, 
per day
$828 AHRQ HUCP [82]
Day hospital 
treatment, per day
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glucose level or hemoglobin A1c at the time of initiation,
4 months after starting and at 12 months. However,
patients with potentially clinically significant weight gain
are assumed to incur the cost of undergoing metabolic
monitoring every 4 months.
Model Outcome Measures
Clinical Outcomes
The MCM model provides estimates of 3 key clinical out-
comes: the proportion of patients experiencing outpatient
relapse, those experiencing inpatient relapse, and those
without an inpatient or outpatient relapse (stable or no
relapse). The model also yields estimates of the mean
QALYs per patient by medication.
Economic Outcomes
The main economic outcome of the MCM model is total
annual direct health care costs. The model also reports
mean total direct health care costs for 4 selected out-
comes: cost of stable days, cost of inpatient relapse, cost of
outpatient relapse, and cost of adverse events. Finally, the
MCM model reports the total annual medication cost of
each antipsychotic medication.
Cost-Effectiveness Information
The cost-effectiveness measure in the model is the incre-
mental cost-effectiveness ratio (ICER), which was calcu-
lated as the difference in costs between 2 comparators
divided by their difference in QALYs. In this study, we
assumed that any ICER in the $50,000–$100,000 range
was cost-effective [85].
ICERs have traditionally been calculated relative to no treat-
ment. However, "no treatment" is not an appropriate option
for persons with schizophrenia. As a result, the model calcu-
lates the ICER for every nondominated treatment.
Results
Two sets of results are presented in this paper. First, we
report the MCM model results using all baseline assump-
tions. Then we summarize the results of the 5 sensitivity
analyses conducted.
Clinical Outcomes
Figures 2 and Figure 3 display a complete set of base case
clinical results for the 5 comparators in the model. For the
base case, Figure 2 indicates that olanzapine would result
in more patients never experiencing relapse, fewer inpa-
tient relapses, and fewer outpatient relapses. In addition,
Figure 3 indicates that olanzapine would result in a lower
number of relapses per patient and the highest QALY of
any medication studied.
Economic Outcomes
Figure 4 displays base case estimates of the total mean
direct medical cost, as well as predicted costs for each of
the key cost components for all comparators in the model.
For total mean direct medical cost, the base case of the
model predicted that olanzapine results in the least costly
option among the 5 comparators. Figure 4 also demon-
strates the mean annual direct costs varied by selected cost
component by medication. For example, olanzapine had
the highest annual medication acquisition cost but the
lowest annual mean cost of treating relapse of the 5 com-
parators.
Cost-Effectiveness
The incremental cost per QALY gained of 1 comparator
versus another is a widely recognized metric of cost effec-
tiveness. A treatment that produces more QALY at a higher
cost may be cost effective if the resulting ICER is below a
stated threshold. As seen in Figure 3 and Figure 4, olanza-
pine was predicted to result in the highest mean QALY per
patient and the lowest total mean direct medical cost. As
a result, from a cost-effectiveness perspective, olanzapine
was the dominant therapy in terms of cost/QALY gained
because it is predicted to produce more QALYs at a lower
cost. Moreover, Figures 3 and 4 show that olanzapine was
dominant in 1-to-1 comparisons with each comparator in
the same manner. Finally, risperidone dominated
quetiapine, ziprasidone, and aripiprazole producing more
QALY at a lower cost. One-way and probabilistic sensitiv-
ity analyses were conducted to examine the stability of the
base case results.
One-Way Sensitivity Analyses Results
One-way sensitivity analysis was performed to assess the
impact of important variables on model outcomes and
patient subgroups. First, Table 8, Test 1, reports the results
of the sensitivity analysis for adherence subgroups simu-
lated in the model. These results were calculated by
assuming that all patients had the same adherence level.
First, we simulated the model with a cohort of fully adher-
ent patients and recorded the mean total direct medical
cost by medication and the cost per QALY for olanzapine.
The same process was applied to a cohort of partially
adherent patients and then a cohort of nonadherent
patients. The results from this sensitivity test indicate that
risperidone has the lowest total cost if all patients remain
fully adherent ($7,932) or partially adherent ($9,365),
but that olanzapine has the lowest total cost if all patients
are nonadherent ($6,699). In addition, the results for cost
per QALY indicate that olanzapine is the dominant choice
for nonadherent patients and a cost-effective option for
partially adherent patients (ICER of $44,718) and for fully
adherent patients (ICER of $82,519).
Table 9, Test 2 displays results for 1-way analysis was per-
formed to assess the impact of 2 treatment-emergent
adverse event rates on model outcomes: diabetes and
hyperlipidemia. Literature-based rates [84] for treatment-
emergent diabetes were used as upper bounds for all com-Cost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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Base Case Clinical Outcomes Figure 2
Base Case Clinical Outcomes.
Base Case Clinical Outcomes – Inpatient Relapse and Mean QALYs Gained Figure 3
Base Case Clinical Outcomes – Inpatient Relapse and Mean QALYs Gained.Cost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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parators. The upper limits for hyperlipidemia were based
upon a California Medicaid Study [71]. The model results
indicated that olanzapine remained the dominant strat-
egy (highest mean QALY and lowest mean direct cost)
when incorporating alternate adverse event rates that were
higher than the base case rates. Sequential bifurcation
indicated that EPS and treatment-emergent clinically sig-
nificant weight gain did not directly impact model results
and were not included in the sensitivity analysis.
Table 10, Test 3, reports the results of sensitivity analysis
associated with changing the rates of relapse expressed as
hospitalization risk ratios. The first column of this table
shows the base case hospitalization risk ratio reported in
the CATIE, phase 1 [23]. This sensitivity analysis was per-
formed by increasing the hospitalization risk ratio of
olanzapine to each comparator which has the effect of
increasing the costs of olanzapine versus each compara-
tor. The values in the second column show the hospitali-
zation risk ratios for each comparator required to make
the total mean direct cost of olanzapine therapy roughly
the same as the comparator. The values in the third col-
umn are the hospitalization risk ratios at which olanzap-
ine was more costly, but relatively cost-effective in terms
of cost per QALY (approximately $50,000).
Table 11, Test 4, reports results of the first of 2 head-to-
head analyses between olanzapine and risperidone. The
Table 8: Test 1: Sensitivity – Adherence Subgroups

















RIS $9080 $7877 $9290
(Base)
$9367
QUE $13619 $11856 $13473 $14267
ZIP $11414 $9882 $11301 $12003
ARIP $11603 $10191 $11547 $12090
ICER = incremental cost-effectiveness ratio; OLZ = olanzapine; RIS = risperidone; QUE = quetiapine; ZIP = ziprasidone; ARIP = aripiprazole
Base Case Economic Outcomes Figure 4
Base Case Economic Outcomes.Cost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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results in Table 11, Test 4, answer the following questions:
At what relative rates of inpatient relapse does risperidone
become cost-neutral when compared to olanzapine, and
at what relative rate of inpatient relapse does risperidone
dominate olanzapine? The first row of Table 11, Test 4,
reports the base case results for comparison. The second
row indicates that the hospitalization risk ratio of risperi-
done compared to olanzapine would need to drop to 1.54
for the 2 medications to be cost-neutral. The final row
indicates that the hospitalization risk ratio of risperidone
compared to olanzapine would have to be 0.70 for risperi-
done to begin dominance of olanzapine.
Table 12, Test 5, presents results of the second head-to-
head analysis between olanzapine and risperidone and
reports the sensitivity analysis associated with changing
the generic price of risperidone below baseline rate of $5
per day. The second row of this table assumes that risperi-
done is reduced to 13¢ per day (initiatives by major U.S.
retailers). At this price, olanzapine remains cost-effective
($10,246 per QALY) relative to risperidone. Finally the
last row indicates that olanzapine remains cost-effective
even if risperidone is acquired at zero cost.
Probabilistic Sensitivity Analysis Results
Figure 5 reports the percentile of the cohorts, in the head-
to-head comparison of olanzapine to risperidone, which
had an ICER below the selected cost thresholds in
$50,000 increments, starting with all cohorts where olan-
zapine was found to be dominant graphed at $0. The
results of the first PSA (randomly sampled input values for
adherence rates, relapse rates, treatment discontinuation
rates, and the generic cost of risperidone) are displayed as
the lower curve, while the upper curve reports the results
of the second PSA (adding randomly sampled input val-
ues for the number and cost of resources consumed for
stable patients (no relapse), patients experiencing inpa-
tient relapse, and patients experiencing outpatient
relapses to the variables in the first PSA). The results of the
first PSA (upper curve in Figure 5) indicate that olanzap-
ine compared to risperidone was cost saving (dominant)
in 59% of the 1,000 cohorts simulated. Further, the results
of the first PSA found that olanzapine compared to risp-
eridone had an ICER of $50,000 or less in 84% of the
cohorts simulated, an ICER of $100,000 or less in 93% of
the cohorts, and an ICER of $125,000 or less in approxi-
mately 96% of the cohorts simulated. The results of the
Table 9: Test 2: Adverse Event Rates
Treatment-Emergent Diabetes Treatment-Emergent Hyperlipidemia
New Event Rate*
(Base Case Rate)
Total Mean Cost QALYs ICER Cost/QALYs New Event Rate**
(Base Case Value)
Total Mean Cost QALYs ICER Cost/QALYs
OLZ 4.6%
(3.3%)




















$11632 0.710 - 16.7%
(3.6%)
$11678 0.707 -
*Source: Leslie and Rosenheck, 2005 [84]
**Source: Olfson et al., 2006 [70]
QALYs = quality-adjusted life years; ICER = incremental cost-effectiveness ratio; OLZ = olanzapine; RIS = risperidone; QUE = quetiapine; ZIP = 
ziprasidone; ARIP = aripiprazole
Further analysis showed that olanzapine remained dominant when the rates of diabetes for aripiprazole and ziprasidone were kept at the base case 
value and all others were increased.
Table 10: Test 3: Sensitivity Analysis – Changing CATIE Relapse Risk Ratios
Olanzapine/CATIE Ratio Cost-Neutral Ratio Cost-Effective Ratio (ICER @ $50000)
RIS 0.64* 0.65 0.73 ($45,385)
QUE 0.44 0.88 0.89 ($60,767)
ZIP 0.57 0.75 0.80 ($43,236)
ARIP 0.57 0.77 0.80 ($44,187)
*Base case ratio from CATIE Phase 1 [23] which reported hospitalization risk ratios normalized to 1 person year of exposure: RIS = 0.45, OLZ = 
0.29 thus olanzapine/risperidone = 0.64.
CATIE = Clinical Antipsychotic Trials of Intervention Effectiveness; ICER = incremental cost-effectiveness ratio; RIS = risperidone; QUE = 
quetiapine; ZIP = ziprasidone; ARIP = aripiprazoleCost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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second PSA (lower curve in Figure 5) indicates that even a
greater proportion of the 1,000 cohorts met each of the
selected ICER thresholds than in the first PSA in the direct
comparison of olanzapine to risperidone. In the second
PSA, olanzapine was reported to be cost-saving in 50% of
the cohorts and had an ICER of $50,000 or less in 74% of
the cohorts, while approximately 93% of the cohorts had
an ICER of $125,000 or less. Figure 5 reports the propor-
tion of cohorts that selected cost-effectiveness thresholds
between $0 and $400,000 because a recent review of cost-
effective research in the United States suggested that no
single cost-effectiveness threshold is necessarily appropri-
ate and that U.S. policy makers often use different thresh-
olds for different policy issues [85].
Discussion
This is the first cost-effectiveness analysis to compare oral
generic risperidone with various oral atypical antipsychot-
ics in the usual treatment of patients with schizophrenia
in the United States. Results of the MCM model's baseline
assumptions, along with results of selected sensitivity
analyses, found olanzapine to be a cost-effective therapeu-
tic strategy for patients with schizophrenia, even if a 30-
day pharmacy fill of oral generic risperidone were to cost
$4 per month or less. The MCM model's baseline assump-
tions predict that the utilization of olanzapine provides
better clinical outcomes and lower total health care costs
compared to generic risperidone, quetiapine, ziprasidone,
and aripiprazole. Furthermore, the latter 3 medications
were dominated by both olanzapine and generic risperi-
done. Specifically, compared to the second most cost-
effective treatment strategy (generic risperidone), olanza-
pine was associated with a lower rate of inpatient relapse
(16% vs. 25%), with higher QALY (0.733 vs. 0.719) and
with lower total health care cost ($8,544 vs. $9,080).
Sequential bifurcation found that the relapse rate result-
ing in either inpatient hospitalization or outpatient care is
the most significant baseline assumption in the MCM
model. Because olanzapine therapy offers patients a lower
propensity for relapse than its comparators, a sensitivity
analysis was conducted to determine the change in relapse
rates required by risperidone to make olanzapine cost-
neutral and then just cost-effective. This head-to-head
comparison indicated that risperidone is cost-neutral if
the hospitalization risk ratio is reduced to 1.54 (RIS/OLZ)
from the baseline assumption of 1.55, and risperidone
achieves dominance only after the hospitalization risk
ratio is reduced to 0.70. This suggests that risperidone
would need to generate a 30% risk reduction in hospital-
ization relapse rates relative to olanzapine. The implica-
tion of this sensitivity analysis is that olanzapine is a
dominant or cost-effective treatment option over a wide
range of relapse rates that likely represent a plausible
range of clinical scenarios for patients with schizophrenia.
Additional sensitivity tests indicated that the impact of
CHD events, as driven by treatment-emergent diabetes
and hyperlipidemia, had minimal impact on overall
mean annual medical cost or cost per QALY. For example,
the net impact of increasing the rate of treatment-emer-
gent diabetes for olanzapine from the base rate of 3.3%
[69] to 4.6%, the value of Leslie and Rosenheck [84], only
added $19 annually to the total medical cost for olanzap-
ine. Further, increasing the base rate of hyperlipidemia to
a higher, literature-based value increased the mean annual
direct medical cost of olanzapine by $38 [71]. These
results remain robust despite the fact that they are
assumed to occur in the first quarter of treatment initia-
tion, rather than weighing the increase in the rates over
the 4 quarterly cycles.
In summary, the cost-effectiveness estimates in our MCM
model are sensitive to the baseline assumption that in the
treatment of patients with schizophrenia, olanzapine is
associated with a lower risk of relapse compared to risperi-
done, quetiapine, ziprasidone, and aripiprazole. Since the
cost of relapse is the core driver, it is important to under-
Table 11: Test 4: Sensitivity Analysis Olanzapine Versus 
Risperidone: Changing CATIE Relapse Risk Ratios to Achieve 
Desired ICER Result
ICER
RIS/OLZ Ratio OLZ RIS
1.55 (Base Case)* Dominant -
1.54 Cost-Neutral
0.70 Effectiveness-Neutral
*Base case ratio from CATIE Phase 1 [23] which reported 
hospitalization risk ratios normalized to 1 person year of exposure: 
RIS = 0.45, OLZ = 0.29, and RIS/OLZ = 1.55.
ICER = incremental cost-effectiveness ratio; RIS = risperidone; OLZ = 
olanzapine
Table 12: Test 5: Sensitivity Analysis Olanzapine Versus Risperidone: Changing Only the Cost of Generic Risperidone
Cost Per Day of Therapy for Generic Risperidone OLZ
Mean Annual Direct Cost
RIS
Mean Annual Direct Cost
ICER
$5.00 (Base) $8581 $9120 OLZ Dominant
$0.13 $8557 $8408 $10,246
$0 $8557 $8389 $11,509
OLZ = olanzapine; RIS = risperidone; ICER = incremental cost-effectiveness ratioCost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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score that the relapse rates in this model were based on the
NIMH-sponsored CATIE trial [23]. In addition, this MCM
model's baseline assumption is supported by other
research, conducted across geographies and methodolo-
gies, in which olanzapine was found to achieve lower
relapse rates or have longer time to relapse compared to
risperidone [64,85-87], quetiapine [40,88-90], and
ziprasidone [39,48].
It is also notable that although we used the CATIE find-
ings to support the model's assumption that olanzapine is
more effective than the comparators (risperidone,
quetiapine, ziprasidone, and aripiprazole), our assump-
tion received recently additional support from the first
meta analysis of head-to-head comparisons of 9 second-
generation antipsychotics in the treatment of schizophre-
nia [91]. That comprehensive meta-analysis, which
included the 5 antipsychotics studied in our model, also
showed that olanzapine proved superior to risperidone,
quetiapine, ziprasidone, and aripiprazole. In addition, the
authors examined potential sponsorship bias and con-
cluded that exclusion of studies sponsored by pharmaceu-
tical companies did not change the results.
Findings of this cost-effectiveness analysis are consistent
with prior research [13,17,18,57,92,93] that also found
psychiatric hospitalization to be the largest cost compo-
nent in the treatment of schizophrenia and medication
costs to comprise the second most costly type of resource
[17,18]. Also consistent with prior research [19] were the
findings that treatment-emergent EPS and diabetes fol-
lowing initiation of therapy with atypical antipsychotics
do not lead to substantial cost implications because of
their low incidence. Most importantly, current findings
are consistent with other cost-effectiveness studies
[49,58,92-97] showing that olanzapine therapy is more
effective and less or as costly (total direct medical costs)
compared to studied atypical antipsychotics, because
olanzapine is associated with a lower rate of inpatient
hospitalization, the main driver of the cost differentials.
Since our cost-effectiveness model is sponsored by Eli
Lilly and Company, the manufacturer of olanzapine,
skepticism about potentially biased industry-sponsored
economic models prevails [98,99]. However, the findings
reported in this paper are consistent with recent cost-effec-
tiveness analysis conducted by Leeuwenkamp and col-
leagues [93] and sponsored by Organon and Pfizer. That
study found that initiation with olanzapine (compared to
risperidone) lowered the number of relapses at 1 year and
increased the proportion of patients remaining on treat-
ment. As a result, the study concluded that starting with
olanzapine rather than risperidone may result in more
time without symptoms and lower nonmedication health
care costs during the first year of treatment. Another inde-
pendent cost-effectiveness analysis [92], comparing vari-
ous antipsychotics, including oral olanzapine,
risperidone, quetiapine, and ziprasidone, found olanzap-
ine to be the most effective treatment with the highest pro-
portion of patients remaining free of psychiatric
hospitalization. In this study, quetiapine and ziprasidone
were found to be dominated by olanzapine while oral ris-
peridone was found to be less effective and less costly but
with higher incremental cost-effectiveness ratio than olan-
zapine.
The results reported in this paper are, however, inconsist-
ent with 4 cost-effectiveness models in the literature.
These studies found risperidone was more cost-effective
than all other comparators including olanzapine [18,100-
102]. These models assumed, however, that olanzapine
and risperidone therapy achieved the same medication
adherence level [18,100,102] and the same risk of relapse
[18,100,101]. In addition, these models assumed that ris-
peridone-treated patients had a shorter length of hospital
stay than olanzapine-treated patients and that risperidone
is more efficacious than olanzapine [102]. The sensitivity
analysis reported in this paper suggest that risperidone
would be a cost-effective treatment strategy if we assumed
different baseline inputs concerning relapse rates, length
of hospital stay, and adherence levels.
The MCM model developed and tested in this paper has a
number of strengths. The baseline assumptions are docu-
mented and transparent, using inputs and key model out-
puts that are relevant for comparative economic
evaluation of atypical antipsychotics in the treatment of
schizophrenia. The structure of the model reflects the
essential features of the disease and its treatment proc-
esses by simulating the dynamic nature of usual care
where patients switch, continue, discontinue, and restart
their antipsychotics. The baseline assumptions are rela-
tively conservative, using input parameters that are based
Proportion of Cohorts At or Below Selected ICER Thresh- olds Figure 5
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on the published literature and evidence available in the
public domain. For example, we have chosen a relatively
low number of inpatient days of hospitalizations associ-
ated with relapses compared to other models (11.7 vs.
23.1) [18,82]. Auxiliary sensitivity analysis showed that
increasing the number of inpatient days strengthened
olanzapine's cost-effectiveness and dominance. The
model allows for changes in all input parameters shown
to impact the costs of treating schizophrenia using
sequential bifurcation tests. The model findings are also
robust as demonstrated by a diverse sensitivity analyses to
assess the potential for variation in the model results. And
lastly, although our microsimulation model may seem
complex, it is important to note that simpler methods
implicitly need the same inputs but tend to hide the
assumptions that are explicit in our model. We feel that by
being transparent we more accurately capture the complex
and dynamic nature of the disease and its treatment proc-
esses.
Our model has, however, a number of limitations. First,
lack of published medical literature for some model input
parameters (e.g., QALYs by health states and adherence
levels) required using expert panel opinions. In addition,
lack of head-to-head randomized studies comparing all 5
studied SGAs required making assumptions that need fur-
ther study (e.g., that aripiprazole and ziprasidone have the
same clinical and safety features). Second, the model does
not include all SGAs currently available in the United
States, thus excludes clozapine and paliperidone. This
exclusion was made a priori since this model focused only
on the most frequently used SGAs, and clozapine and pal-
iperidone are used infrequently in the United States.
Third, the model used a 1-year time horizon although
schizophrenia is a life-long illness. While this follow-up
duration is used in most other schizophrenia cost-effec-
tiveness models, it may not be sufficiently long to observe
changes in costs and outcomes over the course of a
chronic illness. In particular, it may also not allow for
accurate assessment of specific treatment-emergent
adverse events such as CHD and tardive dyskinesia which
usually take longer to develop. Indeed, when the CATIE
data was used to estimate the 10-year CHD risk for each of
the treatment groups [103], it found this risk has signifi-
cantly increased for olanzapine-treated patients (+0.5%),
whereas it significantly decreased for the ziprasidone and
risperidone treatment groups (-0.6%). It is notable, how-
ever, that when estimating 10-year CHD risk, one assumes
the patients will continue on the current antipsychotic
during the following 10 years. This is a questionable
assumption considering the highly dynamic and changing
nature of treatment for schizophrenia in the United States.
It is also important to recognize there is only 1 rand-
omized longitudinal study comparing actual cardiac
adverse events in patients treated with different antipsy-
chotics rather than on projected estimates of CHD risk.
This was the Ziprasidone Observational Study of Cardiac
Outcomes (ZODIAC) [48], a 1-year study of 18,154
patients with schizophrenia, conducted in 18 countries.
This study did not find significant differences between the
treatment groups with respect to cardiac events (e.g., inci-
dence of cardiovascular mortality or hospitalization for
various cardiac conditions). Moreover, consistent with
our model's assumptions, ZODIAC found a significantly
higher rate of treatment discontinuation and a higher rate
of psychiatric hospitalization for the ziprasidone-treated
patients compared to the olanzapine treatment group.
ZODIAC was, however, only 1 year long, thus not suffi-
ciently long to capture changes in cardiometabolic risk in
patients treated with various antipsychotics.
A fourth limitation of the model is its focus on direct cost
and exclusion of indirect cost, which can be substantial in
the treatment of schizophrenia [3]. Finally, the model did
not take into account that some patients have pre-existing
adverse events and conditions, including diabetes and
hyperlipidemia [104,105], which may impact future costs
and outcomes. Additional research is needed to help iden-
tify which patients with what profiles respond best to
which antipsychotic after failure on specific medications
for what reasons.
Results of our cost-effectiveness model also need to be
evaluated in a larger context, considering that we focused
only on specific SGAs and did not address the compara-
tive cost-effectiveness of first- and second-generation
antipsychotics (FGAs and SGAs). This is a topic of much
debate about whether the more costly SGAs have superior
benefits compared with lower-cost FGAs. This debate
may, however, become less relevant for payers, including
U.S. payers who may have little incentive to use FGAs fol-
lowing patent expiry of SGAs, such as risperidone and
their availability in generic form and lower cost. Nonethe-
less, studies have reached different conclusions regarding
the cost-effectiveness of 1 or more SGAs versus FGAs
[17,49,57]. The cost-effectiveness analysis of the CATIE
[17] showed that a low potency FGA (perphenazine) was
more cost-effective than SGAs, including olanzapine.
Another study, conducted in the UK (CUtLASS1) [57],
also reported that FGAs may be cost-saving and associated
with a gain in QALYs compared with SGAs. This ongoing
debate was further fueled by findings of a new compre-
hensive meta-analysis of SGAs versus FGAs [106] showing
that 4 specific SGAs (clozapine, amisulpride, olanzapine,
and risperidone) are better than FGAs for overall efficacy,
whereas the other SGAs (including quetiapine, ziprasi-
done, and aripiprazole) are not better. The authors sug-
gested abandoning the classification of antipsychotics
into FGA and SGA since each is not a homogeneous class,
and improper generalization creates confusion. TheyCost Effectiveness and Resource Allocation 2009, 7:4 http://www.resource-allocation.com/content/7/1/4
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pointed out that SGAs differ on many properties, includ-
ing efficacy, adverse events, cost, and pharmacology. Our
cost-effectiveness model avoided comparisons between
drug classes and focused instead on 5 specific SGAs that
differ in their efficacy, adverse events, pharmacology, and
cost.
Conclusion
The utilization of olanzapine is predicted in this micro-
simulation model to result in better clinical outcomes and
lower mean total health care costs – from the perspective
of payers in the U.S. health care system – compared to
generic risperidone, quetiapine, ziprasidone, and arip-
iprazole. Olanzapine is, therefore, projected to be a cost-
effective therapeutic option for patients with schizophre-
nia in the United States, even with oral risperidone avail-
able in generic form and cost. This model simulates real-
world treatment processes and provides projections that
should be used only to inform decision-making processes
from the U.S. health care system perspective. Although
current findings are consistent with several previous stud-
ies, this model – as any other economic model – will
require revision and validation of baseline assumptions
when new and additional relevant scientific data are avail-
able.
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